FirsthandHealth
medRxiv PreprintsInternational9 November 2026

Provider-Level and Specialty Variation in ARNI and SGLT2i Use After Heart Failure Hospitalization

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are incompletely utilized in heart failure with reduced ejection fraction (HFrEF). The degree to which use varies at the individual level and within specialties is unknown. We aimed to characterize provider-level and specialty-level variation in ARNI and SGLT2i prescribing after HF hospitalization. Methods: This retrospective cohort study included Veterans Affairs (VA) providers seeing patients within 6 months of HFrEF hospitalization 2017-2023. We used descriptive statistics an
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.